Objective To assess possible adverse effects on breastfed infants of mothers receiving
monoclonal antibodies (MAbs) during pregnancy and/or lactation. Methods We identified 23 …

Objective To determine the transfer of the monoclonal antibody natalizumab into breastmilk
and to evaluate drug and serum neurofilament light chain ((s) NfL) levels in natalizumab …

Background: Managing medication during pregnancy and lactation in multiple sclerosis
(MS) patients needs to balance potential risks to the newborn with the substantial risks of …

Importance Natalizumab reduces multiple sclerosis relapses very effectively; however,
severe disease activity may return once natalizumab treatment is withdrawn, as …

Purpose of Review There is considerable heterogeneity in the use of B-cell depletion in
women of childbearing age, likely driven at least in part by the discrepancy between the …

Background: Natalizumab, a therapeutic monoclonal antibody approved for the treatment of
relapsing–remitting multiple sclerosis (RRMS), is recommended to be withdrawn 3 months …

Objective To evaluate risks of disease reactivity during pregnancy and postpartum following
rituximab (RTX) and natalizumab (NTZ) suspension in women with MS. Methods An …

Background: Safety data on first-trimester natalizumab exposure are scarce, as natalizumab
is usually withdrawn three months before pregnancy. Objective: The objective of this paper …

Objective To report pregnancy outcomes and disease activity (DA) in women with MS,
neuromyelitis optica spectrum disorders (NMOSDs), and other neuroimmunologic diseases …

Importance The magnitude of risk of pregnancy-related multiple sclerosis relapses,
particularly severe relapses, following natalizumab cessation is unclear, as is whether this …